MedTrace Logo

GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results

NCT05183243 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-07-16

No results posted yet for this study

Summary

Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors.

Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.

Conditions

Interventions

DRUG

GH21 Capsule

GH21 for oral administration at doses of Dose A, Dose B, Dose C, Dose D, Dose E and Dose F.

Sponsors & Collaborators

  • Suzhou Genhouse Bio Co., Ltd.

    lead OTHER

Principal Investigators

  • Haidan Wang, Doctorate · 0512-86861608

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-20
Primary Completion
2024-12-31
Completion
2025-02-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05183243 on ClinicalTrials.gov